Novo Nordisk A/S
Narrative signal
Novo Nordisk A/S’s revenue growth stands at 25% for Dec 2024. Year-over-year, the metric shifted by −6.2 pts, translating into a −19.91% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
Valuation Signals
Track how the market prices earnings, book value, and operating cash flow for rapid context on relative multiples.
Price-to-Earnings Ratio
27.5x
Price-to-Sales Ratio
9.6x
Price-to-Book Ratio
19.4x
EV / EBITDA
20.9x
Dividend Yield
1.6%
Profitability Pulse
Follow margin structure and return ratios that benchmark execution quality and capital efficiency.
Growth Momentum
Gauge the trajectory of revenue, earnings, and free cash flow expansion to understand durability.
Cash & Balance Sheet
Monitor liquidity, leverage, and free cash flow capacity that underpin resilience across cycles.
AlphaPilot quick take
• Novo Nordisk A/S trades at $47.86 with a market footprint around $212.7B.
• Operating within Healthcare — Drug Manufacturers - General offers instant peer context.
• Dashboard highlight: revenue growth at 25%, refreshed from the live fundamentals feed.
• Pivot into AlphaPilot deep dives to benchmark valuation, execution, and resilience.
Company profile
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Novo Nordisk A/S (NVO) stock FAQs
Quick answers sourced from live Financial Modeling Prep fundamentals and AlphaPilot portfolio guidance.
What is Novo Nordisk A/S (NVO) stock price today?
Novo Nordisk A/S (NVO) trades near $47.86 as of Dec 5, 2025, 9:01 PM. Quotes refresh throughout the trading day in USD via Financial Modeling Prep, which powers the AlphaPilot dashboard.
What is Novo Nordisk A/S's market capitalization?
Novo Nordisk A/S's equity is valued around $212.7B, based on the latest share price multiplied by shares outstanding reported to Financial Modeling Prep.
What is the 52-week range for Novo Nordisk A/S?
Novo Nordisk A/S's 52-week range runs from $43.08 — $112.52. Comparing the current price to this band helps visualize positioning versus the past year's highs and lows.
How active is trading in Novo Nordisk A/S stock?
Novo Nordisk A/S most recently moved about 15.3M shares. Elevated volume often signals strong investor interest or fresh catalysts.
Does Novo Nordisk A/S pay a dividend?
Novo Nordisk A/S currently yields roughly 1.6%. Dividend yield divides the last 12 months of payouts by the latest share price, providing a quick income snapshot.
What is Novo Nordisk A/S's intraday trading range?
Novo Nordisk A/S has traded between $47.84 — $49.12 so far today. Monitoring the intraday span highlights short-term volatility relative to the longer 52-week range.
Where does the Novo Nordisk A/S stock data come from?
AlphaPilot sources quotes, fundamentals, and intraday chart data for Novo Nordisk A/S from the Financial Modeling Prep institutional API. The summary page blends live pricing with fundamentals that refresh after every earnings release or regulatory filing.